- Delivering Pan India
Zelgor® (Abiraterone Acetate) Abiraterone acetate 250 mg tablets by BDR Pharmaceuticals. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Abiraterone acetate 250 mg |
|---|---|
| Manufacturer | BDR Pharmaceuticals |
| Country | India |
| Pack size | Abiraterone acetate 250 mg: 120 tablets |
| Storage | As per carton and leaflet; original pack |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Zelgor® (Abiraterone Acetate) Abiraterone acetate 250 mg Tablets — CYP17 Inhibitor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Zelgor® is a brand of abiraterone acetate 250 mg tablets, an oral CYP17 inhibitor. According to the US prescribing information for the reference product (Zytiga®), abiraterone acetate is indicated in combination with prednisone for metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC). Indications for Zelgor in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe abiraterone acetate, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Zelgor® (abiraterone acetate) Abiraterone acetate 250 mg tablets to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Zelgor contains abiraterone acetate 250 mg per tablet. The Zelgor carton shown on this page states abiraterone acetate tablets 250 mg, 120 tablets, for oral use.
How it works, according to the label: The reference label describes abiraterone acetate as a CYP17 inhibitor given with prednisone, together with a GnRH analog or after bilateral orchiectomy.
The current US prescribing information for ZYTIGA® (abiraterone acetate tablets) (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Zelgor pack insert.
The Zytiga label summarises its Clinical Studies, including COU-AA-302 in chemotherapy-naive metastatic CRPC (Ryan et al., New England Journal of Medicine, 2013) and the LATITUDE trial in high-risk metastatic CSPC. Full results are in the DailyMed prescribing information. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Abiraterone acetate 250 mg | Tablets (oral) | 120 tablets |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology and urology department buyers, and pharmacies that source oral oncology products. Abiraterone is prescribed and supervised by a physician, as described in the prescribing information.
The Zytiga label lists, as most common adverse reactions (10% or more), fatigue, joint pain, hypertension, nausea, edema, low potassium, hot flush, diarrhea, vomiting, upper respiratory infection, cough and headache. Its warnings cover mineralocorticoid excess (hypertension, hypokalemia, fluid retention), adrenocortical insufficiency, hepatotoxicity, increased fractures and mortality with radium Ra 223, embryo-fetal toxicity and hypoglycemia. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Zelgor carton and leaflet. For reference, the US Zytiga label describes storage at controlled room temperature, 20°C to 25°C. Keep in the original pack, out of reach of children.
Zelgor is marketed by BDR Pharmaceuticals. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Zelgor through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Zelgor available in India?
A.K. Pharma supplies Zelgor (abiraterone acetate) Abiraterone acetate 250 mg tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Zelgor contain?
Abiraterone acetate 250 mg per tablet, an oral CYP17 inhibitor, in a pack of 120 tablets.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Zelgor be stored?
As printed on the carton and leaflet, in the original pack.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
